EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Carbapenem-Sparing Therapy of ESBL- Enterobacterales Pyelonephritis: A Retrospective Comparison of Cefoperazone-Sulbactam and Meropenem

Zahid Hussain, Aamir Sikander Kazi, Imtiaz Hussain, Hira Saleem, Hira Nadeem, Samreen Sarfaraz

Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University · 26.06.2026 · 22 (3) · 319-326

DOI: 10.48036/apims.v22i3.1690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University, online erschienen am 26.06.2026. Verfasst von Zahid Hussain und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the real-world clinical outcomes, time to clinical cure of patients with Extended-spectrum b-lactamase-producing Enterobacterales (ESBL-E) pyelonephritis who received cefoperazone-sulbactam versus meropenem based on retrospective medical record review.

Objective

To compare the real-world clinical outcomes, time to clinical cure of patients with Extended-spectrum b-lactamase-producing Enterobacterales (ESBL-E) pyelonephritis who received cefoperazone-sulbactam versus meropenem based on retrospective medical record review. Methodology: A retrospective cohort study was done at the Department of Infectious Diseases, Indus Hospital and Health Network (IHHN), Karachi, on adult patients with culture-proven ESBL-producing Enterobacterales pyelonephritis treated between January 2008 and December 2024. Data were collected using a structured questionnaire that captured demographic characteristics, clinical findings, and outcomes, including survival status, physician-assessed clinical improvement, infection-related complications, hospitalization, mortality, and clinical status at follow-up.

Results

Overall mean age of 48.9+15.81 years and females were in majority 119 (73.5%) compared to males 43 (26.5%). Meropenem-treated patients had higher baseline severity, with higher SOFA scores (3.7 vs 2.3, p = 0.002), Charlson Comorbidity Index (3.6 vs 2.0, p = 0.001), compared to cefoperazone-sulbactam-treated cases. However, the primary and secondary outcomes were statistically comparable across the groups: in terms of composite clinical failure which occurred in 6.3% (meropenem) versus 6.1% (cefoperazone-sulbactam) p = 1.000, relapse in 12.6% versus 4.5% (p = 0.101), and 30-day mortality in 5.3% versus 0.0% (p = 0.077), with no significant differences in rehospitalization rate and microbiological non-response.

Conclusion

Cefoperazone–sulbactam appeared to be a clinically feasible and effective carbapenem-sparing alternative to meropenem for the treatment of ESBL-producing Enterobacterales pyelonephritis. Although it was used more frequently in less critically ill patients, it was associated with clinical and microbiological outcomes comparable to those observed with meropenem.

Results

Overall mean age of 48.9+15.81 years and females were in majority 119 (73.5%) compared to males 43 (26.5%). Meropenem-treated patients had higher baseline severity, with higher SOFA scores (3.7 vs 2.3, p = 0.002), Charlson Comorbidity Index (3.6 vs 2.0, p = 0.001), compared to cefoperazone-sulbactam-treated cases. However, the primary and secondary outcomes were statistically comparable across the groups: in terms of composite clinical failure which occurred in 6.1% (meropenem) versus 6.3% (cefoperazone-sulbactam) p = 1.000, relapse in 12.6% versus 4.5% (p = 0.101), and 30-day mortality in 5.3% versus 0.0% (p = 0.077), with no significant differences in rehospitalization rate and microbiological non-response.

Conclusion

Cefoperazone–sulbactam appeared to be a clinically feasible and effective carbapenem-sparing alternative to meropenem for the treatment of ESBL-producing Enterobacterales pyelonephritis. Although it was used more frequently in less critically ill patients, it was associated with clinical and microbiological outcomes comparable to those observed with meropenem.

Zitieren

APA

Hussain, Z., Kazi, A. S., Hussain, I., Saleem, H., Nadeem, H., & Sarfaraz, S. (2026). Carbapenem-Sparing Therapy of ESBL- Enterobacterales Pyelonephritis: A Retrospective Comparison of Cefoperazone-Sulbactam and Meropenem. Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University, 22(3), 319-326. https://doi.org/10.48036/apims.v22i3.1690

Vancouver

Hussain Z, Kazi AS, Hussain I, Saleem H, Nadeem H, Sarfaraz S. Carbapenem-Sparing Therapy of ESBL- Enterobacterales Pyelonephritis: A Retrospective Comparison of Cefoperazone-Sulbactam and Meropenem. Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University. 2026;22(3):319-326. doi:10.48036/apims.v22i3.1690

BibTeX
@article{Hussain2026,
  author = {Hussain, Zahid and Kazi, Aamir Sikander and Hussain, Imtiaz and Saleem, Hira and Nadeem, Hira and Sarfaraz, Samreen},
  title = {Carbapenem-Sparing Therapy of ESBL- Enterobacterales Pyelonephritis: A Retrospective Comparison of Cefoperazone-Sulbactam and Meropenem},
  journal = {Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University},
  year = {2026},
  volume = {22},
  number = {3},
  pages = {319--326},
  doi = {10.48036/apims.v22i3.1690}
}
Kostenlos starten →